Martin S. Maron, MD

Learn when cardiac myosin inhibitors suffice and when myectomy or alcohol ablation fits, with shared decisions at expert HCM centers.

MAPLE HCM reveals aficamten beats beta blockers in obstructive HCM, reshaping first-line therapy debates amid insurance hurdles.

Explore how aficamten’s shorter half-life enables faster titration, flexible echo monitoring, and fewer drug interactions—making HCM treatment more patient-friendly and accessible.

When beta blockers fall short in obstructive HCM, explore myosin inhibitors, disopyramide, or septal reduction—and see why patients breathe easier.

When beta blockers fall short in obstructive HCM, explore myosin inhibitors, disopyramide, or septal reduction—and learn why patients breathe easier.

Learn key hypertrophic cardiomyopathy symptoms and how echoes with Valsalva or exercise reveal hidden LVOT obstruction for accurate diagnosis.

Panelists discuss the signs, symptoms, diagnostic delays, and classification of obstructive hypertrophic cardiomyopathy, including how it differs from other forms and its implications for clinical management.

Panelists discuss the challenges and gaps in diagnosing hypertrophic cardiomyopathy, including variability in clinical practice, underdiagnosis, and opportunities to improve detection.

Maron and Masri define the ongoing role of surgical myectomy and alcohol septal ablation in the myosin inhibitor era and preview emerging trials of aficamten in nonobstructive HCM.

Maron and Masri discuss whether myosin inhibitors, particularly aficamten, should be considered first-line therapy for symptomatic obstructive HCM in treatment-naive patients, in light of data from trials like MAPLE-HCM.

Maron and Masri review pivotal phase 3 trials of mavacamten and aficamten and explain how efficacy and systolic function monitoring shaped their respective REMS programs.

Maron and Masri introduce cardiac myosin inhibitors—mavacamten and aficamten—explaining their sarcomere-level mechanism and the rationale for targeting hypercontractility in obstructive HCM.

Maron and Masri review decades of experience with beta-blockers, calcium channel blockers, disopyramide, and septal reduction therapies, underscoring persistent under-treatment and the unmet need that set the stage for myosin inhibitors.

In this opening segment, Martin (Marty) Maron, MD, and Ahmed Masri, MD, PA-C, introduce the discussion and frame obstructive hypertrophic cardiomyopathy (HCM) as the central focus, emphasizing outflow tract gradients as the key driver of symptoms.

Expert cardiologists share strategies for educating patients on the treatment and management of hypertrophic cardiomyopathy.

Drs Steve R. Ommen, Martin S. Maron, Javed Butler, and James Januzzi provide insight on the evolving treatment landscape for obstructive hypertrophic cardiomyopathy.

A panel of experts in cardiovascular medicine review the use of mavacamten as seen in the VALOR-HCM study for patients with symptomatic oHCM who are eligible for septal reduction therapy.

Martin S. Maron, MD, examines long-term data with mavacamten for oHCM treatment that was presented at ACC 2022.

Cardiac specialists discuss improvement in health status with different treatments for hypertrophic cardiomyopathy.

John A. Spertus, MD, MPH, and Martin S. Maron, MD comment on the role of mavacamten in oHCM as seen in the EXPLORER-HCM trial.

Steve R. Ommen, MD, discusses the use of novel agents in the pipeline for the treatment of obstructive hypertrophic cardiomyopathy (oHCM).

Steve R. Ommen, MD, leads a discussion on factors to consider when choosing treatment for hypertrophic cardiomyopathy (HCM).

Experts in cardiology review invasive treatments, challenges with HCM treatments, and how to optimize treatment for patients.

Drs Javed Butler, Martin S. Maron, Steve R. Ommen, and James Januzzi provide insight on approaching treatment of HCM with pharmacologic and nonpharmacologic interventions.

Steve R. Ommen, MD; and Martin S. Maron, MD, review the role of AHA/ACC guidelines, imaging techniques, and circulating biomarkers in approaching the diagnosis and treatment of hypertrophic cardiomyopathy.

John A. Spertus, MD, MPH, comments on the effect of oHCM on health status and quality of life for patients.

Drs Steve R. Ommen, Martin S. Maron, John A. Spertus, Javed Butler, and James Januzzi provide insight on the presentation of nonobstructive and obstructive hypertrophic cardiomyopathy.

Steve R. Ommen, MD, leads a review of common mutations seen in hypertrophic cardiomyopathy and the role of biomarkers and genetic testing in HCM.

Martin S. Maron, MD, discusses the incidence and prevalence of hypertrophic cardiomyopathy and age of disease expression.